We are a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics that target lipid-signaling modulation pathways, including the endocannabinoid system (the “ECS”), a network of receptors and neurotransmitters that form a biochemical communication system throughout the body.
Partnerships Exclusive worldwide license from NEOMED Institute (adMare Bioinnovations)
Indications
Cancer anorexia cachexia syndrome(Phase 2)
Status note Phase 1b/2a CAReS study of cancer-related anorexia; filing reports an interim analysis of the ongoing Phase 2a portion. Filing describes a synthetic oral formulation developed for this use. 10-K fallback classifies the program as a cannabinoid GPCR agonist.
Status note IND application submitted with FDA study-may-proceed notice received July 8, 2024; CIPN prioritized as initial indication; diabetic neuropathy also explored. 10-K fallback classifies the program as a cannabinoid GPCR agonist.
ART12.11
Discovery · Active
Partnerships n/a (wholly owned)
Indications
Anxiety(Discovery)
Status note Internal discovery research initiative; CBD co-crystal composition. Filing states an anxiety strategy became a priority based on results; no clinical stage stated.
Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.